Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
TruBrain is a leading brand in high-performance cognitive nutrition with over $11....
TruBrain is a leading brand in high-performance...
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectr...
The Ensign Group, Inc.'s independent operating ...
Medivie Therapeutic is an Israeli public company, which developed Laboraide â a ...
Medivie Therapeutic is an Israeli public compan...
Tenax Therapeutics is focused on developing and commercializing pharmaceutical pro...
Tenax Therapeutics is focused on developing and...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical ...
Adial Pharmaceuticals, Inc. ("the Company") is ...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...
Cyclacel's founding scientist, Professor Sir Da...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Join the National Investor Network and get the latest information with your interests in mind.